Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10029


Purpose:

1. The MyoVista device is capable of detecting surface electrocardiogram signals and sensitive in detecting coronary artery disease compared to traditional computed tomography angiography (CTA) 2. Electrophysiological signals at the cellular level of myocardium are related to specific patterns on the MyoVista device 3. Changes in MyoVista device output and can indicative of future CAD outcomes and need for revascularization


Study summary:

Background Myocardial ischemia is caused by myocardial oxygen supply and demand mismatch. Despite that coronary artery disease (CAD) is the major cause of myocardial ischemia, the symptoms may occur even in the absence of significant CAD. One of the mechanisms suggested for myocardial ischemia in these patients is microvascular ischemia (i.e. mismatch in microscopic vessels), affecting the myocardium (i.e. heart muscle) at the cellular level. A novel electrocardiographic recording method, the iECG is capable of capturing and amplifying signals from the cellular level that are much lower biologic signals than those processed by a traditional electrocardiogram (ECG). These recordings focus on early detection of myocardial abnormalities by non-linear analysis of electrical activity and physiological phenomenon. This novel assessment might be capable of detecting subclinical myocardial dysfunction in a variety of heart diseases. Specific Aims Aim#1: Study the feasibility of detection of CAD using iECG compared to computed tomographic coronary angiography (CTA). Aim#2: Study the association between patterns of iECG and myocardial dysfunction in patients without CAD compared to echocardiography. Aim#3: Study the effect of changes in iECG output on future outcomes of CAD and need for revascularization.


Criteria:

Inclusion Criteria: - Sinus rhythms - Age>18 years - Both genders Exclusion Criteria: - Acute coronary syndromes(ACS) - Contraindications to the administration of iodinated contrast - Pregnancy - Coronary artery bypass surgery (CABG) - History of cardiac valvular replacement - Implanted cardiac pacemaker - Chest deformities - Unwilling or unable to provide informed consent for study participation - Enrolled in another clinical study


NCT ID:

NCT02560168


Primary Contact:

Principal Investigator
Partho P Sengupta, MD, DM, FACC, FASE
Icahn School of Medicine at Mount Sinai


Backup Contact:

N/A


Location Contact:

New York, New York 10029
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.